LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Drug Combinations with Transplantation for Myeloma.

    Jethava, Yogesh S / Barlogie, Bart / Tricot, Guido J

    The New England journal of medicine

    2017  Volume 377, Issue 1, Page(s) 91–92

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols ; Drug Combinations ; Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma ; Transplantation, Autologous
    Chemical Substances Drug Combinations
    Language English
    Publishing date 2017--06
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1705671
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Transplantation for Multiple Myeloma.

    Jethava, Yogesh S / van Rhee, Frits

    Cancer treatment and research

    2016  Volume 169, Page(s) 227–250

    Abstract: Multiple myeloma is a disorder characterized by accumulation of malignant plasma cells in the bone marrow, hypercalcemia, monoclonal protein, and end organ damage. Recently newer generation proteosome inhibitors, monoclonal antibodies and novel agents ... ...

    Abstract Multiple myeloma is a disorder characterized by accumulation of malignant plasma cells in the bone marrow, hypercalcemia, monoclonal protein, and end organ damage. Recently newer generation proteosome inhibitors, monoclonal antibodies and novel agents have been approved by FDA, which is undoubtedly increasing life expectancy of the patients. However, hematopoietic stem cell transplantation still remains the cornerstone of the treatment. In this chapter, we are discussing the autologous stem cell transplant, allogeneic stem cell transplant and total therapy trials with outcomes.
    MeSH term(s) Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma/therapy
    Language English
    Publishing date 2016
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 0927-3042
    ISSN 0927-3042
    DOI 10.1007/978-3-319-40320-5_13
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

    Jonsdottir, Gudbjörg / Lund, Sigrún H / Björkholm, Magnus / Turesson, Ingemar / Hultcrantz, Malin / Porwit, Anna / Jethava, Yogesh S / Landgren, Ola / Kristinsson, Sigurdur Y

    Blood advances

    2017  Volume 1, Issue 25, Page(s) 2392–2398

    Abstract: In the present study, we aimed to evaluate 2 hypotheses. First, we hypothesize that prior malignancy is a proxy for genetic susceptibility that could be a risk factor for subsequent malignancy development in multiple myeloma (MM) patients. Second, we ... ...

    Abstract In the present study, we aimed to evaluate 2 hypotheses. First, we hypothesize that prior malignancy is a proxy for genetic susceptibility that could be a risk factor for subsequent malignancy development in multiple myeloma (MM) patients. Second, we hypothesize that survival after MM is influenced by a prior malignancy. All patients diagnosed with MM from 1 January 1973 to 31 December 2010 were identified from the Swedish Cancer Register. Cox regression model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) where prior malignancy was compared in MM patients who developed a subsequent malignancy and MM patients who did not. In another Cox regression model, survival was compared in MM patients with and without a prior malignancy diagnosis. A total of 19 791 patients were diagnosed with MM. Patients with a prior malignancy diagnosis had a significantly increased risk of developing a subsequent malignancy compared with MM patients without (HR 1.42, 95% CI 1.23-1.65,
    Language English
    Publishing date 2017-11-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2876449-3
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2017007930
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.

    Jethava, Yogesh S / Mitchell, Alan / Epstein, Joshua / Zangari, Maurizio / Yaccoby, Shmuel / Tian, Erming / Waheed, Sarah / Khan, Rashid / Papanikolaou, Xenofon / Grazziutti, Monica / Cottler-Fox, Michele / Petty, Nathan / Steward, Douglas / Panozzo, Susan / Bailey, Clyde / Hoering, Antje / Crowley, John / Sawyer, Jeffrey / Morgan, Gareth /
    Barlogie, Bart / van Rhee, Frits

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2017  Volume 23, Issue 11, Page(s) 2665–2672

    Abstract: Purpose: ...

    Abstract Purpose:
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Chromosome Aberrations/drug effects ; Disease-Free Survival ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Metaphase/drug effects ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Neoplasm Proteins/genetics ; Prognosis ; Prospective Studies ; Thalidomide/administration & dosage ; Thalidomide/adverse effects
    Chemical Substances Neoplasm Proteins ; Thalidomide (4Z8R6ORS6L) ; Bortezomib (69G8BD63PP) ; Melphalan (Q41OR9510P)
    Language English
    Publishing date 2017-06-01
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-15-2620
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top